Acne

NEW YORK — Dermatologists must treat post-inflammatory hyperpigmentation simultaneously with acne in patients with skin of color, which can be done using lasers, according to a study presented here.

IDP-126 gel, which is a combination of clindamycin, adapalene and benzoyl peroxide, showed positive results in patients with moderate to severe acne, according to a study.

Post-acne scarring should be treated as a distinct condition from acne vulgaris and deserves a comprehensive and unique clinical approach, according to a study.

Acne is one of the most common skin disorders that affects a wide range of individuals but specifically targets those aged 12 to 24 years. In fact, 85% of people in this age range experience acne, according to Yale Medicine.

Molecular changes in barrier function and inflammatory markers characterized the pathophysiology of atopic dermatitis at age 1 month, according to a study published in the Journal of the European Academy of Dermatology and Venereology.

While some adolescents treated with isotretinoin for moderate to severe acne vulgaris reported mood-changes, a majority experienced improvement in symptoms and completed treatment, according to a study.

A new gel for treating acne vulgaris is set to undergo FDA review with the agency’s acceptance of a new drug application for investigational IDP-126, according to a press release from Bausch Health.

The fixed-combination IDP-126 showed promising results as the first triple-combination product for the treatment of acne in patients aged as young as 9 years, according to a study.

NEW ORLEANS — Trifarotene monotherapy, a convenient topical treatment, offers clinical efficacy, safety and tolerability in adolescents with moderate facial and truncal acne vulgaris, according to a poster presented here.

While tumor necrosis factor-alpha inhibitors have shown positive results in the treatment of acne, the use of these inhibitors for other conditions may incite new acne development, according to a study.